Vialwirebiotech, curated
September 30, 2026, 5:49 PM
September 22, 2026
- 4:30 PM · Nikkei Asia4:30 PMRoche-owned Chugai Pharma to ramp up in-house output with 50% capex boost — Nikkei Asia
- 2:31 PM · BioPharma Dive2:31 PMAmgen reports a Phase 3 win with Sjögren’s drug candidate — BioPharma Dive
- 12:31 PM · Pharmaceutical Executive12:31 PM<![CDATA[Nine European Drugmakers Warn the Continent Risks Losing the Pharma Investment Race: Report ]]> — Pharmaceutical Executive
- 12:10 PM · BioPharma Dive12:10 PMViking shares surge on updated obesity drug data — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMSino Biopharm nears approvals with HER2 ADC, IL-4R antibody filings — BioWorld
- 12:00 PM · BioWorld12:00 PMHighlife secures $90M+ to advance its TMVR system — BioWorld
- 12:00 PM · BioWorld12:00 PMDLL3 drug race expands beyond bispecific T-cell engagers — BioWorld
- 12:00 PM · BioWorld12:00 PMUncertainty continues as Wuxi Apptec haunted by listing — BioWorld
- 12:00 PM · BioWorld12:00 PMSK Biopharm takes 1st Bio’s LRRK2/c-Abl inhibitor in $315M deal — BioWorld
- 12:00 PM · BioWorld12:00 PMDialybrid raises €15M for Silkothane Arteriovenous Graft — BioWorld
- 12:00 PM · BioWorld12:00 PMChina syndrome? Phase II wins for Cue in CSU, stock melts down — BioWorld
- 12:00 PM · BioWorld12:00 PMCompass drops on FDA feedback for tovecimig in biliary cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMSecond Chimagen deal extends GSK's China innovation strategy — BioWorld
- 12:00 PM · BioWorld12:00 PMRegcell adds $66M to take Nobel-winning Tregs to clinic — BioWorld
- 11:42 AM · BioPharma Dive11:42 AMCelldex sinks as safety concerns cloud immune drug results — BioPharma Dive
- 10:23 AM · STAT News
- 9:20 AM · TechCrunch9:20 AMSingapore’s Nexstrom wants to bring 2D semiconductors to chip fabs — TechCrunch
- 9:00 AM · BioWorld9:00 AMHengrui patents new KRAS mutant inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMBeone describes new Keap1/CUL3 interaction inducers — BioWorld
- 9:00 AM · BioWorld9:00 AMMaat Pharma schedules pre-IND meeting for MaaT-034 — BioWorld
- 9:00 AM · BioWorld9:00 AMKymera Therapeutics discloses new STAT6-targeting PROTACs — BioWorld
- 9:00 AM · BioWorld9:00 AMIndupro details preclinical characterization of lead oncology program — BioWorld
- 9:00 AM · Labiotech (EU)9:00 AMAstraZeneca’s pipeline strategy: building the next wave of growth — Labiotech (EU)
- 9:00 AM · BioWorld
- 9:00 AM · PharmaVoice9:00 AMCRO consolidation keeps rolling. What does that mean for pharma? — PharmaVoice
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMFDA final rule provides flexibility for nonanimal testing — BioWorld
- 9:00 AM · BioWorld9:00 AMBeactica begins IND-enabling studies for BEA-17 — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMNew deals boost Novo Nordisk’s AI drug discovery ambitions — Drug Discovery World
- 7:00 AM · BioPharma Dive7:00 AMA hidden tradeoff in Trump’s drug pricing deals — BioPharma Dive
- 6:00 AM · Drug Discovery World6:00 AMScottish deep-tech company secures £22 million in grants — Drug Discovery World
- 5:31 AM · Pharmaceutical Technology5:31 AMMade Scientific acquires cell therapy facility in Pennsylvania, US — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMNovartis faces September’s fourth trial disappointment with ALS drug — Drug Discovery World
- 4:50 AM · Pharmaceutical Technology4:50 AMEC approves Menarini and NewAmsterdam’s obicetrapib therapies — Pharmaceutical Technology
September 21, 2026
- 2:20 PM · Pharmaceutical Executive2:20 PM<![CDATA[Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Lambic]]> — Pharmaceutical Executive
- 12:45 PM · Nikkei Asia12:45 PMJapan aims to ensure domestic vaccine production capacity for next crisis — Nikkei Asia
- 12:00 PM · BioWorld12:00 PMIntrabio’s Aqneursa wins FDA nod as first ataxia-telangiectasia drug — BioWorld
- 12:00 PM · BioWorld12:00 PMBeacon readies BLA after pivotal win with ocular gene therapy — BioWorld
- 12:00 PM · BioWorld12:00 PMEMA says no to conditional approval of Maat's Xervyteg — BioWorld
- 11:08 AM · STAT News11:08 AMSTAT+: Lilly’s breast cancer combo wins approval — STAT News
- 10:36 AM · Pharmaceutical Technology10:36 AMBeijing unveils blueprint for biomedical dominance by 2030 — Pharmaceutical Technology
- 10:14 AM · Pharmaceutical Executive10:14 AM<![CDATA[Roundup: AbbVie & Lambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM ]]> — Pharmaceutical Executive
- 9:52 AM · Pharmaceutical Executive9:52 AM<![CDATA[CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report ]]> — Pharmaceutical Executive
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMEli Lilly discovers new KRAS (G12D mutant) inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMMaze Therapeutics discloses new SLC6A19 inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMChengdu Zeling Biomedical Technology identifies new PARP-1 inhibitors — BioWorld
- 7:30 AM · BioPharma Dive7:30 AMHow J&J paved the way for Compass’ coming psychedelic drug launch — BioPharma Dive
- 7:00 AM · Drug Discovery World7:00 AMRoche and Dualitas Therapeutics agree $1b bispecific antibodies deal — Drug Discovery World
- 7:00 AM · STAT News
- 6:00 AM · Drug Discovery World6:00 AMDeep Science Ventures veterans launch Big Picture Bio — Drug Discovery World
- 5:33 AM · STAT News
- 5:00 AM · Drug Discovery World5:00 AMCircio raises NOK 200 million towards in vivo CAR-T programme — Drug Discovery World
- 3:38 AM · Pharmaceutical Technology3:38 AMSandoz and mAbxience agree on emicizumab biosimilar partnership — Pharmaceutical Technology
September 20, 2026
- 7:25 PM · STAT News7:25 PMSTAT+: Radiopharma companies merge after one receives surprise FDA rejection — STAT News